GALTライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases...

Stats
本日の出来高	173 828
平均出来高	153 496
時価総額	213.57M
EPS	$0 ( 2024-04-04 )
次の収益日	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.66
ATR14	$0.0130 (0.38%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-24	Lewis Joel	Buy	1 000	Common Stock
2023-12-31	Czirr James C	Buy	0
2024-04-22	Czirr James C	Sell	21 323	Common Stock
2024-04-23	Czirr James C	Sell	3 677	Common Stock
2024-04-22	Freeman Kevin D	Buy	2 500	Common Stock

INSIDER POWER
24.13
Last 97 transactions
Buy: 4 256 891 \| Sell: 2 389 317

ボリューム相関

長: 0.23 (neutral)

短: -0.75 (moderate negative)

Signal:(40.806) Neutral

Galectin Therapeutics Inc 相関

10 最も正の相関
BRACU	0.946
KIN	0.945
ALGM	0.929
ACVA	0.929
NCAC	0.925
CLBT	0.921
PEGA	0.92
NSIT	0.92
AMYT	0.919
SRRA	0.919

10 最も負の相関
DCRC	-0.928
AHPI	-0.923
IMV	-0.922
NCBS	-0.921
TENX	-0.92
LAWS	-0.919
CFMS	-0.919
TSHA	-0.918
VWE	-0.917
SGLB	-0.914

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Galectin Therapeutics Inc 相関 - 通貨/商品

0.12
( neutral )

0.70
( moderate )

0.00
( neutral )

0.64
( weak )

-0.24
( neutral )

-0.71
( moderate negative )

Galectin Therapeutics Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-33 000.00 (0.00 %)
EPS:	$-0.680

FY	2023
収益:	$0
総利益:	$-33 000.00 (0.00 %)
EPS:	$-0.680

FY	2022
収益:	$0
総利益:	$-32 000.00 (0.00 %)
EPS:	$-0.660

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.520

Financial Reports:

No articles found.

Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.